Atlas.
Sign inStart free trial
NVCRNASDAQ · US

NovoCure Ltd

Technology · Surgical & Medical Instruments & Apparatus

TechnologySurgical & Medical Instruments & Apparatus
CEO
Frank Leonard
Founded
—
IPO Date
—
HQ
St. Helier
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$15.78 ▲ 20.3%
Last (1 Jul 2026) · $16
Period High · $18.31
Period Low · $10.03
52W: $10.03 – $18.46

Key Metrics

Share Price
$15.78
+4.2% today
Market Cap
$1.8B
P / E
—
EV / Revenue
2.9x
Revenue Growth
+8.3%
year-on-year
Gross Margin
+74.5%
Enterprise Value
$1.9B
52W High
$18.46
52W Low
$10.03
Avg Volume
1.5M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
13 known institutional holders·$458M total on record·2026-Q1
Fmr LLC
15.2%·$186M
BlackRock, Inc.
11.8%·$144M
State Street Corp
2.3%·$28M
Geode Capital Management, LLC
2.2%·$27M
Renaissance Technologies LLC
1.4%·$17M
Point72 Asset Management, L.P.
1.2%·$15M
Dimensional Fund Advisors LP
0.9%·$10M
Jpmorgan Chase & Co
0.8%·$10M
Northern Trust Corp
0.8%·$10M
Goldman Sachs Group Inc
0.7%·$8M
Bank Of America Corp
0.2%·$2M
Invesco Ltd.
0.1%·$1M
Price T Rowe Associates Inc
0.1%·$1,255
Free Float
62.3%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for NovoCure Ltd
OverviewNovoCure Ltd share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow NovoCure Ltd generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsNovoCure Ltd's complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityNovoCure Ltd executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsNovoCure Ltd's annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for NovoCure Ltd, updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for NovoCure Ltd aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersNovoCure Ltd valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for NovoCure Ltd with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for NovoCure Ltd — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial